SENS
Senseonics Holdings, Inc.·Healthcare
6.32
1.711%(−0.11)
Close PriceLast Updated: — ET
52W L: $4.7952W H: $12.58
SENS NEWS
marketbeat.com
May 8
Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system and the integration of its U.S. commercial organization.
seekingalpha.com
May 8
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
zacks.com
May 7
Senseonics Holdings (SENS) Reports Q1 Loss, Beats Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.4 per share a year ago.
globenewswire.com
May 7
Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results
Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update.
globenewswire.com
May 4
Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants. Senseonics sold 10,400,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 2,400,000 additional shares of common stock, and 8,000,000 pre-funded warrants. The shares of common stock were sold at a price to the public of $5.00 per share and the pre-funded warrants were sold at a purchase price of $4.999 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics from the offering were approximately $92.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Senseonics.
globenewswire.com
May 4
Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to transform lives in the global diabetes community, announced that it has entered into a Second Amendment to the Loan and Security Agreement with Hercules Capital, Inc. (NYSE: HTGC).
